Lupin reports completion of FDA inspection at Vizag plant with no observations

Lupin said that the US Food and Drug Administration (FDA) has wrapped up a pre-approval and GMP inspection of its API manufacturing plant in Visakhapatnam, Andhra Pradesh.

The FDA inspection was undertaken from 6 March to 10 March 2023 and was completed without any observations.

Nilesh Gupta — Lupin Managing Director said: “We are pleased with the successful completion of the inspection at our Vizag facility.

“This accomplishment is a testament to our commitment to upholding global quality standards across all our manufacturing sites, and to provide quality affordable healthcare for all.”